ArticleAnnals of hematology2026
Development and validation of a radiomics nomogram for predicting outcomes following combined radiotherapy and modern chemotherapy in early-stage extranodal nasal-type NK/T-cell lymphoma: a multicenter study.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Compared with existing clinical prognostic indicators, the prognostic efficacy of radiomics in predicting outcomes for early-stage extranodal nasal-type NK/T-cell lymphoma(ENKTCL) patients who received combined radiotherapy and non-anthracycline-based chemotherapy is still unclear. This study aims to construct and validate a hybrid radiomics nomogram based on multicenter data. A total of 196 patients from Xijing Hospital were enrolled and were randomly divided into the training set (n = 147) and internal validation set (n = 49) at a ratio of 3:1, and 57 patients from the other three hospitals were used as the independent external validation set. Important radiomic features selected from 1316 features extracted from contrast-enhanced CT-based tumors were used to calculate radscore as the radiomic signature. The optimal clinical index was selected from four common models: International Prognostic Index(IPI), Korean Prognostic Index(KPI), prognostic index for NK/T-cell lymphomas(PINK), and nomogram-revised risk index(NRI), which was combined with radscore to construct a hybrid nomogram for predicting overall survival(OS). Twelve radiomic features that were most useful to predict OS were ultimately selected to calculate radscore. Compared with PINK, IPI, and KPI, NRI demonstrated superior prognostic performance. Furthermore, the radscore model outperformed NRI. A hybrid nomogram, named RadNRI, was constructed by integrating NRI and radscore. The RadNRI model demonstrated the highest performance with C-index of 0.815, 0.823 and 0.765 in the training, internal and external validation sets, respectively. A hybrid radiomics nomogram was constructed and validated in multicenter data, which demonstrates significant potential in forecasting prognosis of early-stage ENKTCL patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.